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Abstract 
The treatment of cartilage defects poses a clinical challenge owing to the lack of intrinsic regenerative 
capacity of cartilage. The use of tissue engineering techniques to bioengineer articular cartilage is 
promising and may hold the key to the successful regeneration of cartilage tissue. Natural and synthetic 
biomaterials have been used to recreate the microarchitecture of articular cartilage through multilayered 
biomimetic scaffolds. Acellular scaffolds preserve the microarchitecture of articular cartilage through a 
process of decellularization of biological tissue. Although promising, this technique often results in poor 
biomechanical strength of the graft. However, biomechanical strength could be improved if biomaterials 
could be incorporated back into the decellularized tissue to overcome this limitation. 
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The treatment of cartilage defects poses a clinical challenge due to the lack of intrinsic regenerative 
capacity of cartilage. The use of tissue engineering techniques to bioengineer articular cartilage is 
promising and may hold the key to the successful regeneration of cartilage tissue. Natural and 
synthetic biomaterials have been used to recreate the microarchitecture of articular cartilage 
through multilayered biomimetic scaffolds. Acellular scaffolds preserve the microarchitecture of 
articular cartilage through a process of decellularisation of biological tissue. Although promising, this 
technique often results in poor biomechanical strength of the graft. Biomechanical strength could be 
improved however, if biomaterials could be incorporated back into the decellularised tissue to 
overcome this limitation. 
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Background 
Cartilage damage can result in pain and loss of function for many patients, and the 
management of moderate to severe defects has been difficult due to the lack of intrinsic capacity for 
cartilage to regenerate [1,2]. The fibrocartilage formed differs substantially from hyaline cartilage; 
therefore the goal is to form regenerative tissue with compressive and hydrodynamic qualities 
similar to hyaline cartilage. Many reports relate compromised function associated with repaired 
cartilage and loss of function of the articular surface [3]. 
Traditional methods of repair of osteochondral defects include debridement, marrow 
stimulation, osteochondral grafting and autologous chondrocyte implantation (ACI) [4-9]. 
Arthroscopic debridement and lavage provides symptomatic relief but does not change the natural 
course of the disease and has similar outcomes to placebo surgery [10,11]. Marrow stimulation, 
usually in the form of microfracture, relies on local recruitment of marrow based stem cells and 
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growth factors to the site of articular repair [12]. The resulting fibrocartilaginous repair does not 
resemble surrounding hyaline cartilage, consisting of less collagen type II [13]. A prospective study 
on microfracture showed good to excellent in 67% of patients following a mean postoperative 
follow-up period of 3.6 years [14]. However, results of microfracture deteriorate over time due to 
the formation of fibrocartilage in the repair tissue [15,16].  
Osteochondral grafting and ACI techniques however aim to regenerate hyaline cartilage. 
Recent 10 year follow-up study showed superior clinical results of osteochondral grafting compared 
with microfracture in young athletes with focal osteochondral defects [17]. An earlier clinical study 
of ACI showed an improvement in symptoms in 14 out of 16 patients at 2 years who had femoral 
condylar lesions [18]. Peterson et al showed good to excellent clinical results following ACI in a 2- to 
9-year followup period, in particular in patients with isolated femoral condyle lesions and 
osteochondritis dissecans of the knee [19]. At 10 to 20 years post ACI implantation, 74% of 224 
patients reported improvements in symptoms [20]. Similarly, Vijayan et al recently reported 12 out 
of 14 patients with good to excellent clinical outcomes at 2 to 8 year followup (average 5.2 years) 
post matrix-induced autologous chondrocyte implantation (MACI) [21]. However in a 5 year long 
term randomised controlled trial, ACI results have been comparable to microfracture, although 
subgroup analysis of that trial showed patients with onset of symptoms less than 3 years had better 
outcome with chondrocyte implantation than microfracture [22]. 
Disadvantages of osteochondral grafting include limitations on donor site availability and 
morbidity [23]. The space between cylindrical grafts may impair the quality of the repair as Lane et al. 
found poor integration of full thickness gaps in experiments in goats [24]. ACI is technically 
challenging with high reoperation rates of 9-20% and associated higher costs [14]. In one study, 36% 
of periosteal patches required debridement of the graft due to periosteal hypertrophy [25]. It also 
requires ex vivo expansion of chondrocytes which necessitates two operations typically at an interval 
of 2 weeks. 
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New products have since been introduced for clinical trials and clinical use. These products 
are based on traditional methods of repair, enhanced with tissue engineering techniques, and are 
summarised in table 1. Although a few have shown some promise, the majority lack long term 
studies and complications have been reported [26,27].  
Although techniques such as osteochondral grafting and ACI have shown improvements over 
microfracture in certain cases, further improvements can be made to increase the longevity and 
consistency of clinical results achieved through current standards of care. As a result substantial 
research continues to focus on advancements in tissue engineering of cartilage to overcome the 
limitation of current repair methods and to develop a bioengineered cartilage regeneration therapy. 
Biomimetic scaffolds using natural and synthetic biomaterials have attempted to reverse engineer 
the complex microarchitecture of hyaline cartilage. Recent developments in acellular biological 
scaffolds, which aim to preserve the native microarchitecture of cartilage to aid in regeneration of 
cartilage defects, may hold the key and the future of articular cartilage regeneration. 
 
Tissue Engineering 
Tissue engineering has the potential to overcome the limitations of current treatment 
options for osteochondral defects. Tissue engineering combines the use of cells, biomaterials and 
stimulatory factors to regenerate and reconstruct the osteochondral unit. 3D tissue grafts can be 
shaped, engineered and tailored to specific needs to improve structural, biological and 
biomechanical properties of current repair processes [28]. 
Cell Source 
Chondrocytes, fibroblasts, stem cells and genetically modified cells have been explored as 
sources for cartilage regeneration, the goal of which is to identify a source that can be reliably used 




Chondrocytes are responsible for the secretion and maintenance of extracellular matrix and 
appear to be the logical cell of choice. Mature chondrocytes secrete type 2 collagen and sulphated 
glycosaminoglycans (GAGs) as extracellular matrix to maintain and remodel the cartilage matrix [29]. 
However the use of chondrocytes is limited by two major concerns. Chondrocytes are limited in 
number comprising only 2-5% of cartilage tissue and thus require expansion prior to use [29-31]. 
Furthermore, the process of expansion and cell culture causes dedifferentiation of mature 
chondrocytes so synthesis of proteoglycans and collagen Type II is decreased and collagen 
expression converts to collagen Type I [32-34]. A variety of methods have been used to prevent or 
limit the degree of dedifferentiation such as three dimensional culture and scaffolds, bioreactors, 
reduced oxygen tension and addition of growth factors such as transforming growth factor β (TGF-β), 
FGF and insulin like growth factor (IGF) [35-40]. These methods have produced hyaline cartilage, 
with varied success, in in-vitro studies. 
Stem Cells 
To avoid the limitations of chondrocytes, mesenchymal stem cells (MSCs) have been used 
for chondrogenesis and osteogenesis [41]. MSCs are found in a variety of human tissue including 
bone marrow, periosteum, synovial membrane, skeletal muscle, dermis, blood and adipose tissue 
[40,42-44]. Bone marrow-derived stem cells (BMSCs) have been most extensively studied. However, 
BMSCs have been shown to express markers showing hypertrophic chondrogenesis (type X collagen 
and MMP-13) that mineralize when exposed to osteogenic stimuli [45-47]. Adipose-derived stem 
cells (ADSCs) are commonly used for the generation of chondrocytes due to their ease of harvest 
and the availability of larger numbers of stem cells [48]. Together with various growth factors such 
as TGF-β and scaffold or culture media, such as alginate or agarose gel, these cells have been shown 
to undergo chondrogenesis with enhanced production of collagen Type II and aggrecan [49-54]. 




Human embryonic stem cells (hESCs) represent an alternative cell source for chondrogenesis 
due to their vast differentiation capacity into various somatic cell lineages and proliferative 
capabilities. A recent study demonstrates the ability for hESCs to undergo efficient chondrogenic 
differentiation using a hyaluronic acid hydrogel method of delivery in a rat model. They also showed 
complete integration of the hESCs engineered cartilage with surrounding cartilage in two-thirds of 
animals without the development of tumours at 12 weeks [56]. Hwang et al showed that 
mesenchymal stem cells derived from hESCs, are capable of multilineage differentiation into fat, 
cartilage and bone in vitro, and achieving normal cartilage architecture in rat osteochondral defect 
repair [57]. 
Recently, induced pluripotent stem cells (iPSCs) have been used to different both osteogenic 
and chondrogenic cell types [58,59]. Like hESCs, iPSCs has the potential to provide great scope for 
cellular expansion and differentiation compared to mesenchymal stem cells, without the same 
ethical problems [60]. There is always a risk of tumourigenicity associated with the use of stem cells 
and in particular the use of viral vectors. Newer methods that generate iPSCs without viral vectors 
have been developed to reduce the risk of tumourigenicity [61-64]. Overall chondrogenic 
differentiation of iPSCs is still in its formative stages of development and further work is required to 
evaluate its full potential in the field of osteochondral regeneration. 
Scaffolds 
Scaffolds provide the environment into which cells can grow and produce cartilage tissue 
and extracellular matrix. As related above, chondrocytes require 3D culture to avoid 
dedifferentiation of their phenotype [65]. Furthermore, the process of dedifferentiation can be 
reversed when chondrocytes are relocated into a three-dimensional (3D) environment [66-68]. 
Scaffolds can be made from a diverse range of materials including natural or synthetic materials or a 
hybrid of both. They can also be designed in forms of hydrogels, sponges, or fibrous mesh. Hydrogels 
support the transportation of cells and bioactive agents and can suspend cells in a three dimensional 
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environment. They can also be injected to fill defects of any size and shape. However they have 
inferior mechanical properties compared with other forms of scaffolds [69]. Sponges are porous 
scaffolds that facilitate cell adhesion. Pore size variation affects cell adhesion, migration and 
deposition [70]. Meshes can also be made to variable porosities governed by fibre diameter and 
direction. They exhibit greater mechanical strength but irregular filling into the mesh itself may 
compromise the quality of the graft and affect tissue integration. 3D constructs of woven fibres and 
electrospinning have been used to mimic the native cartilage material and 3D environment [71,72]. 
Natural materials 
Natural materials used in cartilage engineering include collagen, hyaluronic acid (HA), 
chitosan, alginate, fibrin, silk, gelatin, bacterial cellulose, and cartilage derived matrix. Examples of 
these materials are summarised in table 2 along with their respective advantages and disadvantages. 
Collagen and hyaluronic acid are two of the most common materials used in cartilage engineering 
and clinically most relevant, with many products already in clinical use and trial which are based on 
tissue engineered collagen or hyaluronic acid materials. Thus, these materials will be discussed 
further. 
Collagen has the advantage of being biodegradable, biocompatible and ability to be 
crosslinked [73]. Therefore it is a versatile materials used in tissue engineering. Collagen can be 
formed into different types of scaffolds including sponges, membranes, films, gels and fibres using a 
variety of fabrication methods [74]. Each fabrication method produces a different set of mechanical 
and biochemical properties. Methods that induce pore formation such as freeze-drying process 
result in greater porosity which allows greater cellular and soluble factor infiltration into the 
materials whilst decreases the inherent biomechanical strength of the material [75]. Collagen 
hydrogels are easy to make and forms a gel that can absorb large amounts of fluid which aids in 
cellular infiltration. However in the gel form collagen fibres are not aligned and therefore do not aid 
in manipulation of the microarchitecture of the material to mimic the natural environment [76]. 
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However, in some cases the use of collagen has resulted in a foreign body reaction and poor 
integration with surrounding tissue [2,77]. 
Recently, a two year randomised clinical trial of NeoCart, a collagen type I based bioscaffold 
seeded with autologous chondrocytes cultured in a bioreactor, showed improved clinical outcomes 
compared with baseline and microfracture groups [78]. Adverse events related to the study were 
consistent with those associated with knee arthroscopy. Whilst the results are promising, larger 
studies over longer periods are required before definitive conclusions can be drawn on the efficacy, 
safety and benefit of novel therapies. 
Hyaluronan is an important component of the extracellular matrix of cartilage. Not only does 
it hold water to give compressive strength to cartilage, it also interacts with binding proteins, 
proteoglycans and growth factors which help maintain the ECM structure [79]. Hyaluronic acid (HA) 
is useful in the development of hydrogels due to its negative charge and water-trapping properties 
[80]. HA has been used extensively in tissue engineering not only for bone and cartilage but also in 
liver, cardiac, vascular, dermal, ophthalmic and neural tissue [81]. Mechanical, degradation rates and 
biological function can often be modified and controlled through modification of the HA molecule 
via chemical derivatisation and/or crosslinking with different molecules [82,83]. Toh et al found that 
lower cross-linking improved chondrogenesis of mesenchymal stem cells in a HA based hydrogel 
with increases in the percentage of cells with chondrocytic morphology and improved biosynthesis 
of collagen type II and glycosaminoglycans. Increasing hydrogel cross-linking improved matrix 
stiffness but promoted fibrocartilage formation [84]. HA also exists as fibrous scaffolds in the form of 
Hyaff. Hyaff scaffolds have been shown to allow growth of chondrocytes and support the 
chondrogenic and osteogenic differentiation of mesenchymal stem cells [85,86]. Hyalograft C 
autograft is composed of autologous chondrocytes grown in a 3D Hyaff scaffold, and was first 
introduced into the clinical setting in 1999 for the repair of full thickness cartilage defects [79]. 
Recent prospective clinical case series, with 2 and 7 year follow-up, showed clinical improvement in 
9 
 
young patients with single defects, however for patients with more advanced disease or with 
generalised osteoarthritis the results were poor [87]. 
Synthetic polymers 
Synthetic biodegradable polymers offer an alternative to natural materials for the purposes 
of tissue engineering. These materials offer certain advantages in recreating the complex and 
dynamic nature of native ECM. The key advantage include increased mechanical strength, 
degradation kinetics, versatility of fabrication methods with excellent control over shape, size and 
porosity, as well as the ability to add functional chemical groups to enhance the biological effect of 
the material [88]. Biodegradation has proven to be important in clinical use. Biodegradable polymers 
such as poly(glycolic acid), poly(lactic acid) and their copolymers have been in clinical use since the 
1960s such as in resorbable sutures [89].  Since then many other materials such as poly(dioxanone), 
poly(trimethylene carbonate) copolymers, and poly(ε-caprolactone) have been used in many 
medical devices [90,91]. The ideal polymer must consist of the appropriate mechanical properties to 
match the native ECM whilst allowing sufficient degradation time for tissue healing or regeneration 
to occur. However it must not cause inflammation or toxicity from the material itself or its 
degradation products and ideally be fully metabolized by the body after use [89]. A number of 
materials have been used for cartilage tissue engineering listed in Table 2. 
Poly(α-hydroxy esters) include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), the 
copolymer poly(lactic-co-glycolic acid) (PLGA), and poly(ε-caprolactone) [92]. They are the most 
commonly used synthetic biodegradable polymers for cartilage tissue engineering [93]. PLA exists in 
three isomer forms: poly(L-lactic acid), poly(D-lactic acid), and poly(DL-lactic acid) depending on the 
position of the methyl group [92]. Amongst these poly(L-lactic acid) and poly(DL-lactic acid) are used 
more often as biomaterials. Poly(L-lactic acid) is a semicrystalline polymer exhibiting high tensile 
strength and low elongation making it suitable for load bearing applications such as sutures and 
orthopaedic fixation devices [94,95]. Poly(DL-lactic acid) is an amorphous polymer consisting of a 
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random distribution of each isomer and therefore has lower tensile strength and higher elongation 
and more rapid degradation, therefore making it more useful in a drug delivery system [89]. 
PGA is a highly crystalline polymer with high tensile strength used to develop the synthetic 
absorbable suture known as DEXON® in the 1970 [96]. However PGA also exhibits a high degradation 
rate and low solubility in most organic compounds due to its highly crystalline structure. This can 
result in the accumulation of degradation products which can cause inflammatory reactions [97,98]. 
One major issue with the use of synthetic materials is the acidic degradation by-product of 
the polyester materials. This has been implication in the stimulation of inflammatory reactions as 
well as deactivation of proteins in the surrounding tissue [99]. Therefore, this has led to the 
development of copolymers of the lactides/glycolides with other monomers to form poly(ether 
esters), poly(ester carbonates), poly(ester amides) and poly(ester urethanes) [100-105]. 
Shi et al (2012) used a 3D fibrous poly(L-lactic-co-glycolic acid) (PLLGA) scaffold to repair 
femoral trochlear lesions in rabbit knees. They showed when combined with microfracture the 
repair of full thickness defects was more rapid and efficient when compared to either microfracture 
or scaffold alone. There was positive staining of collagen type II and toluidine blue with good 
integration of repair tissue at 24 weeks [106]. Tru-Fit Plug (Smith & Nephew, Andover, MA, USA) is a 
synthetic resorbable biphasic implant from polyactide-coglycolide copolymer, calcium sulphate and 
polyglycolide. In early results, it  has shown formation of fibrocartilage with inferior biomechanical 
stability when subject to high shear forces in the knee, ongoing articular surface irregularity resulting 
in subsequent arthritic change and delayed integration [107-109]. 
Techniques to accelerate chondrogenesis 
Stimulating factors modulate cell behaviour and this may be by direct biochemical 
interaction or induced by mechanical stimulation. Growth factors commonly used to induce 
chondrogenesis of various cell types. Articular cartilage is subjected to mechanical pressure under 
physiological conditions. Mechanical stimulation such as hydrostatic pressure and dynamic 
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compression techniques have been used to mimic intra-articular conditions and do improve 
chondrogenesis in vitro [110,111]. Furthermore, the addition of growth factors with mechanical 
stimulation seems to produce synergistic effects [112]. 
Growth factors 
Multiple growth factors play an important role in the chondrogenesis of stem cells. The 
transforming growth factor-beta (TGF-β) superfamily contains many which promote chondrogenesis, 
including TGF- β1, TGF- β3, BMP-2, BMP-4, BMP-7, and GDF-5 have been shown to promote 
cartilaginous ECM production [113]. Whilst they all promote cartilaginous ECM production, TGF- β1 
and BMP-2 also down-regulate collagen type I production [114]. Insulin-like growth factor 1 (IGF-1) is 
the main anabolic growth factor in cartilage and controls proteoglycan synthesis and breakdown, 
and induces expression of chondrocyte phenotype [115]. Its effect is independent to the TGF-β 
signalling pathway and therefore when combined leads to additive effects on cartilage matrix 
synthesis [116,117]. Fibroblast growth factor (FGF)-2 and FGF-18 promotes the proliferation of 
chondrocytes and helps to prevent cartilage against damage [118,119]. 
Oxygen tension 
Articular cartilage is avascular with oxygen and nutrients being delivered via passive 
diffusion from synovial fluid [68]. Therefore, articular cartilage exists naturally in a low oxygen 
environment. Hypoxia inducible factor (HIF) mediates transcription factors to allow chondrocytes to 
adapt to low oxygen tension [120]. Hypoxia has been shown to increase the synthesis of ECM 
proteins in vitro in both chondrocytes as well as hypoxia-induced chondrogenic differentiation of 
MSCs [67,121,122]. Hypoxia has also been shown to inhibit the expression of collagen Type X, 
present in fibrocartilage and a marker of chondrocyte hypertrophy [123,124]. Therefore it seems 




Bioreactors are used to improve nutrient transport and provide a fluid-induced shear stress 
to tissues to promote chondrogenesis. Current bioreactors used for cartilage tissue engineering 
include parallel-plate bioreactors, rotating wall bioreactors, and concentric cylinder bioreactors 
[38,125,126]. Lu et al (2012) showed increased deposition of collagen II and glycosaminoglycans 
leading to the formation of cartilage like tissue in a rotating-shaft bioreactor using TGF-β3 expressing 
adipose stem cells[127]. 
Electrical stimulation 
Electrical stimulation has also been employed to induce cartilage and bone repair. In 1974, 
Baker et al. attempted to enhance cartilage repair stimulation of articular cartilage repair by 
electrical means using bimetallic devices inserted into full-thickness articular cartilage defects [128]. 
They demonstrated enhancement of latent potential for repair with hyaline cartilage. The repair 
response appeared to derive from proliferating chondrocytes at the defect margin, with 
encroachment over the surface of the central defect. More recently Brighton et al. reported that 
capacitatively coupled electrical signal resulted in significant up-regulation of cartilage matrix 
protein expression and production while simultaneously significantly attenuating the up-regulation 
of metalloproteinase expression [129]. These results support the contention that delivery of a 
specific, defined electrical field to articular cartilage could result in matrix preservation. They 
concluded that the use of electrical stimulation to both increase matrix production and diminish 
matrix destruction has the promising potential to treat osteoarthritic patients in a non-invasive 
manner. 
Recreating the microarchitecture of articular cartilage 
The biomechanical function of articular cartilage results from the structure of the 
extracellular matrix. The dense network of collagen and proteoglycans in the ECM not only support 
chondrocyte attachment but also transmits mechanical force within the ECM to allow cells to 
respond to mechanical stress [130]. The collagen network provides tensile strength and the 
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proteoglycans, due to their negative charge, maintains high levels of approximately 70% water 
content to resist compressive forces [131]. The intrinsic structure of articular cartilage is further 
organized into three distinct zones: superficial or tangential, middle or transition, deep or radial zone. 
This sits above a layer of calcified cartilage. Each zone has distinct ECM composition, organisation 
and cellular phenotype. Towards the superficial layer the chondrocytes are smaller, thinner, and 
orientated parallel to the articulating surface along with the orientation of the collagen network to 
provide resistance to shear forces [132]. Here chondrocytes also secrete lubricin, otherwise known 
as superficial zone protein, which acts to reduce friction resistance of the cartilage [29,133]. The 
middle zone consists of larger rounded chondrocytes with random collagen orientation with high 
levels of proteoglycans [134]. The deep zone consists of oval chondrocytes with collagen fibres 
forming a vertical or perpendicular alignment. Deep zone cells produce more collagen and 
proteoglycans than the superficial layer however has a lower cell density [131]. 
Biomimetic scaffolds 
Most attempts to date at bioengineering cartilage have focused on using natural and 
synthetic biomaterials, as mentioned previously, to mimic the natural microarchitecture and 
biomechanical properties of native cartilage. Recent examples of such an approach include Kon et al, 
where a multilayered gradient nano-composite scaffold using collagen type I fibrils with 
hydroxyapatite nanoparticles were used in a pilot trial of thirty patients with chondral and 
osteochondral knee lesions [135]. Others have used fibre-hydrogel composite materials to mimic the 
native extracellular structure [136]. More examples are listed in the references of table 2 and many 
have been discussed throughout the course of this review. The advantages and disadvantages of 
each scaffold relate to the materials used. However in general composite materials attempt to 
harness the strengths of each material used. 
Acellular biological scaffolds 
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Acellular scaffolds consist of noncellular parts of a tissue such that collagen and 
carbohydrate structures are maintained in their natural state. Therefore they should maintain the 
appropriate environment for cellular re-attachment, migration, differentiation and proliferation to 
enhance tissue regeneration when transplanted, whilst maintaining, in theory, a perfect 
microarchitecture for the repair tissue (Figure 1) [137]. In recent years decellularised biological 
matrices has been used to regeneration various tissue types including skin, cartilage, bladder, spinal 
cord, and myocardium[138-142].  
A number of studies to date have described the use of acellular cartilage matrices in the 
repair of chondral and osteochondral defects [143,144]. Cheng et al showed acellular porcine 
cartilage-derived matrix was able to support the growth of neocartilage formation in the absence of 
exogenous growth factors [143]. Recently the same group was able to induce chondrogenic 
differentiation of human adipose-derived stem cells without exogenous growth factors on an 
acelluar cartilage matrix crosslinked with genipin to prevent scaffold contraction [145].Schwarz et al 
have shown the successful decellularisation and sterilization of porcine knee and nasal cartilage and 
human nasal cartilage. They also show the ability to remove proteoglycan content whilst maintaining 
the collagen structure. However the decellularisation process also increased the amount of 
denatured collagen compared with native cartilage. Overall there was significant decrease of 
biomechanical loading stress, which the acellular matrix showing reduced stiffness by about 69.5% 
[146]. The matrix did however support the growth of chondrocytes and re-acculumation of 
proteoglycans in the process of in vitro culture [147]. Kang et al also reported the use of 
decellularized cartilage ECM scaffold loaded with adipose stem cells [148]. They used a rabbit 
osteochondral defect model to show adipose stem cell loaded ECM scaffold induced cartilage repair 
tissue comparable to native cartilage in both mechanical and biochemical properties at 6 months. 
Other types of cell-derived matrix (CDM) including fibroblast-derived matrix, preosteoblast-
derived matrix and chondrocyte-derived matrix have been explored and found to support and 
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enhance the growth of chondrocytes and provide a chondro-inductive microenvironment for re-
differentiation of dedifferentiated chondrocytes [149]. 
The primary concern with decellularised extracellular matrix is the loss of biomechanical 
strength and stability during the process of decellularisation. All studies so far have demonstrated a 
loss of mechanical strength as a result of reducing or removing certain components of the 
extracellular matrix in order to achieve decellularisation. 
Lee et al was able to regenerate an entire joint surface of the rabbit proximal humeral joint 
using an acellular bioscaffold created from composite poly-ε-caprolactone and hydroxyapatite 
infused with TGF-β3. They found TGF-β3 infused scaffolds yielded uniform chondrocyte distribution 
across the surface of the bioscaffold and form hyaline-like cartilage expressing collagen type II and 
aggrecan. Furthermore complex microarchitecture of cartilage was recreated as exemplified by the 
formation of stratified avascular cartilage and vascularised bone [150]. This study indicates that 
using acellular scaffolds to provide a suitable environment for endogenous cell recruitment and 
differentiation may be a viable alternative. 
Conclusion and future perspectives 
Injuries to articular cartilage are common, affect people of all ages and cause significant 
morbidity. Cartilage tissue has limited capacity for self-repair and regeneration of fibrous cartilage 
post injury results in numerous attempts at repair. Current approaches may provide adequate long-
term solutions for certain patient groups; however results can often be inconsistent and comparable 
to basic techniques such as microfracture. The implementation of tissue engineering techniques to 
improve traditional methods has culminated in many products being taken to clinical trials for use in 
clinical practice. Early results for some products show some promise; however, results have been 
inconsistent and poor histological repair and complications have been reported.  
Regeneration-based tissue engineering approaches should provide better management of 
articular cartilage defects. However, our complete understanding of the nature of articular cartilage 
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and the processes which govern tissue regeneration are still not completely understood. The optimal 
combination of cells, biomaterials and stimulatory factors to mimic the natural articular 
environment are yet to be defined.  
In our opinion tissue engineering strategies could be improved in the areas of source of cells 
as well as the nature of biomaterials. Recently, the use of iPSCs in the regeneration of bone and 
cartilage tissue in vitro and in vivo has demonstrated a potential role in regenerative orthopaedic 
medicine [58,59]. iPSCs may prove to have a greater capacity for expansion and differentiation. 
However, this technology is in its formative stages and requires development to the stage where 
iPSCs may be used safely in clinical settings. 
We believe that the key to successful regeneration of osteochondral tissue lies with 
recreating not only the composition of the extracellular matrix such as collagen type II and 
proteoglycans, but more importantly creating the complex nano-structure and microarchitecture of 
cartilage tissue itself. Acellular tissue matrix such as acelluar cartilage matrix may provide the best 
possible chance of recapitulating the native microarchitecture of hyaline cartilage in a transplantable 
form for tissue regeneration. However the process of decellularisation may cause destruction of 
microarchitecture resulting in weaker biomechanical strength than expected. This limitation may be 
overcome by augmenting decellularised cartilage with, for example, additional collagen content via 
nanofabrication techniques to improve biomechanical strength and stability. Such hybrid scaffolds 
may benefit from retaining a natural microarchitecture environment whilst improving biomechanical 
strength lost during the decellularisation process. 
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• Cartilage damage is a significant clinical problem and management is difficult due to lack of 
intrinsic regenerative capacity of cartilage tissue. 
• New products aim to improve existing technique through the use of tissue engineering 
strategies. 
Tissue Engineering 
• Tissue engineering combines cells, biomaterials and stimulatory factors to regenerate tissue. 
• Cell sources for cartilage tissue engineering include chondrocytes, mesenchymal stem cells, 
embryonic stem cells and induced pluripotent stem cells. 
• Many scaffold materials have been used to support chondrogenesis, and these materials 
often include the use of natural and/or synthetic materials. 
• The advantages of natural scaffold materials include increased biodegradability, 
biocompatibility, however biomechanical strength can be weaker compared with synthetic 
materials. 
• Synthetic materials such as poly(lactic acid), poly(glycolic acid), poly(caprolactone) and their 
various copolymers provide an alternative to natural scaffold materials, often providing 
greater biomechanical strength. However biodegradation and biocompatibility can be an 
issue which limits their use. 
• Often hybrid natural and synthetic scaffolds are used to complement the strengths and 
weaknesses of each material. 
18 
 
• Stimulatory factors for chondrogenesis include growth factors such as TGF-β, FGF, BMP and 
IGF, mechanical stimulation, hypoxic environments, bioreactors, and electrical stimulation. 
Recreating the microarchitecture of articular cartilage 
• Recreating the microarchitecture of articular cartilage is crucial to achieving normal 
biomechanical function of engineered cartilage. 
• Natural and synthetic materials have been manufactured to mimic the microarchitecture of 
articular cartilage. 
• Acellular cartilage matrix is a viable alternative to preserving the microarchitecture 
environment, thereby creating a scaffold with enhance regenerative capacity  
• The major drawback with acellular cartilage matrix is the loss of biomechanical strength that 
exists with the decellularisation process. 
Conclusion and future perspectives 
• Supplementing decellularized tissue with natural and/or synthetic materials through the use 
of nanofabrication methods could improve the biomechanical properties of decellularized 
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Figure 1: Acellular cartilage matrix retains the natural microarchitecture thereby maintain the 
appropriate environment for cellular re-attachment, migration, differentiation and proliferation to 




Table 1: Products which enhance traditional methods of repair using tissue engineering approaches 





BST-CarGel® [151] Chitosan-glycerol phosphate based hydrogel Piramal Healthcare, Laval, Quebec, 
Canada 
ChonDux™ [152] Photopolymerized hydrogel combined with a 
biological adhesive 
Biomet, Inc., Warsaw, IN, USA 
Gelrin C [153] Polyethylene glycol diacrylate (PEG-DA) and 
denatured fibrinogen hydrogel 











Biodegradable hydrogel implant Salumedica, Smyna, GA, USA 
Chondromimetic 
[154] 
Multilayer triple co-precipitate of collagen, 
glycosaminoglycans and calcium phosphate 
TiGenix, Leuven, Belgium 
Tru-Fit Plug [107-
109] 
Synthetic resorbable biphasic implant from 
polylactide-coglycolide copolymer, calcium 
Smith & Nephew, Andover, MA, USA 
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sulphate and polyglycolide 
Autologous 
chondrocyte 





biomaterials used in 
scaffold 
Carticel [155] Porcine-derived type I and type II collagen 
scaffolds 
Genzyme Inc, Cambridge, MA, USA 
Chondrogide [156] Porcine-derived type I and type II collagen 
scaffolds 
Geistlich Biomaterials, Wolhausen, 
Switzerland 
Hyalograft-C [87] Hyaluronic acid based scaffold Fidia Advanced Biopolymers, Abano 
Terma, Italy), and Neocart 
(Histogenics, Waltham, MA 
Use of bioreactor to 
enhance in vitro 
culture 
Neocart [78] type I collagen matrix Histogenics, Waltham, MA 
Morselized cartilage Cartilage Autograft 
Implantation 
System (CAIS) [157] 
Morselized cartilage DePuy/Mitek, Raynham, MA 
DeNovo Natural Morselized cartilage Zimmer, Inc., Warsaw, IN, USA 
34 
 
Tissue (NT)  [158] 
 
Table 2: 
Table 2: Scaffold materials used for tissue engineering of articular cartilage 




Contains ligands that aid 
in cell adhesion, 
migration and 
differentiation [159] 
Some cases of poor 
integration [77] 
[160]; [161]; [162]; [163]; [39]; 




Fibrin glue can be used 
to enhance integration 
of engineered tissue 
with native cartilage and 
bone 
Weak mechanical strength 
[170] 
 
Rapid degradation [170] 
[171]; [172]; [173]; [174] 
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In vivo injectable options 
[175] 
 




Hyaluronan Hyaluronan hydrogels 
can supplement matrices 
with cells and other 
biomimetics [81] 
Products of biodegradation 
can induce chondrolysis 
[178] 
Hyalograft C [79]; [179]; [180]; [181] 
Chitosan Structurally shares some 
characteristics 




non-toxic and are 
involved in the synthesis 
of articular cartilage 
- Chondroitin sulphate, 
Limited solubility [183] 
 
Certain cross-linkage can 
result in poor 
biocompatibility 
[184]; [185]; [186]; [187]; [188]; 




Hyaluronic acid, Keratin 
sulphate, Glycosylated 
type II collagen 
Bacterial Cellulose Biocompatibility 
 
Match of mechanical 
properties with hard and 
soft tissue 
 
Implantable in gel form 
Lack of direct bond between 
cellulose and bone 
[191] 
Cartilage Derived Matrix Biocompatibility 
 
Support neocartilage 





bioactive molecules that 
interact with cells 
Lower mechanical strength 
and higher rates of 
degradation compared with 
synthesized scaffolds 
 
Chemical cross-linking to 
improve strength can cause 
issues with biocompatibility 
[143]; [144]; [192] 
Gelatin Supports growth of Poor integration with bony [193] 
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chondrocyte layer in 
multilayered scaffold 
 
Uniform porosity allows 
better cell growth and 
proliferation 
structures 
Silk Supports growth of 
chondrocytes 
 
Good tensile strength 
Issues with biocompatibility 
and allergic reactions with 




• Poly(lactic acid) 









Flexibility in degradation 
rates 
Degradation by-products 
has been shown to elicit 
inflammatory response and 
decreased pH level [98] 
 
Mechanical stiffness can 





[197];[198]; [199]; [197]; [200]; 
[201]; [202]; [203]; [204]; [205];; 
[92]; [206]; [207]; [208]; [209]; 
[210]; [211]; [212]; [209]; [213] 






Poly(hydroxyalkanoate) Good biodegradability 
 
Minimal inflammatory 
reaction in vivo 
 
Pizoelectric properties 
Cellular Dedifferentiation [216] 
Poly(vinyl alcohol) Biocompatible 
 
PVA hydrogels have 
similar properties to 
native cartilage 
Poor integration with 
surrounding cartilage 
[162,217] 
Poly (urethane urea) Excellent mechanical and 
biochemical properties 
Polyurethanes using 
polyester diols are 
hydrolytically unstable 
[218]; [219] 
 
 
 
 
